Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 1.00 |
| ▸ | FNTB | P49356 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.83 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.83 |
| ▸ | PTGES | O14684 | 4/20 | 0.81 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.81 |
| ▸ | PREP | P48147 | 1/20 | 0.81 |
| ▸ | CRYAB | P02511 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428550 | 1.00 | FNTA (1.00) | FNTAFNTBMAPTMEN1PLA2G1B | |
| SCHEMBL29512020 | 1.00 | FNTA (1.00) | FNTAFNTBMAPTMEN1PLA2G1B | |
| SCHEMBL899356 | 1.00 | FNTA (1.00) | FNTAFNTBMAPTMEN1PLA2G1B | |
| SCHEMBL20990987 | 0.92 | FNTA (0.84) | FNTAFNTBMAPTMEN1PLA2G1B | |
| SCHEMBL18688329 | 0.92 | FNTA (0.84) | FNTAFNTBMAPTMEN1PLA2G1B | |
| SCHEMBL15118542 | 0.92 | FNTA (0.84) | FNTAFNTBMAPTMEN1PLA2G1B | |
| SCHEMBL18687811 | 0.92 | FNTA (0.84) | FNTAFNTBMAPTMEN1PLA2G1B | |
| Anwuweizonic Acid SCHEMBL18687709 | 0.91 | MAPT (1.00) | FNTAFNTBMAPTMEN1PLA2G1B | |
| Anwuweizonic Acid SCHEMBL20990961 | 0.91 | MAPT (1.00) | FNTAFNTBMAPTMEN1PLA2G1B | |
| Anwuweizonic Acid SCHEMBL12474225 | 0.91 | MAPT (1.00) | FNTAFNTBMAPTMEN1PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996035707-A1 | TERPENOID INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-14 | — | — | WO | claimed |
| WO-2011088126-A2 | TREATMENT OF VIRAL INFECTION WITH PRENYLTRANSFERASE INHIBITORS | EIGER BIOPHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | EXONHIT THERAPEUTICS SA (FR) | 2008-06-26 | — | — | US | disclosed |
| EP-1811984-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Exonhit Therapeutics SA (FR) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051423-A1 | COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON’S DISEASE | EXONHIT THERAPEUTICS SA (FR) | 2006-05-18 | — | — | WO | disclosed |
| EP-1656931-A1 | Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease | Exonhit Therapeutics SA (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-5703067-A | USEFUL IN THE TREATMENT OF CANCER | MERCK & CO., INC. (US) | 1997-12-30 | — | — | US | disclosed |
| WO-1996035707-A1 | TERPENOID INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153758-A1 | Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease | FNTA, GGPS1, FNTB | FNTA 1/4885FNTB 3/4885MAPT 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.